The Racial and Ethnic Inequity in Genomic Medicine -- A Bridge Too Far

Last Updated: July 27, 2021


Disclosure: None
Pub Date: Monday, Jul 26, 2021
Author: Braxton D. Mitchell, PhD, MPH
Affiliation: Department of Medicine, University of Maryland School of Medicine

This is an exciting time for cardiovascular disease research. The sequencing of the human genome has ushered in a new era of genomic research, which during the last decade has led to new avenues for cardiovascular disease prevention and treatment. Results from large clinical population studies and GWAS are being translated into clinical practice to improve risk stratification, 1-4 identify responders and non-responders to pharmacologic agents, 5-7 and develop more personalized approaches to health care. 8 Numerous highly penetrant risk alleles have been identified that are currently being used for genetic testing of patients with presumed heritable forms of heart disease and their family members.9, 10

Regrettably, there are huge inequities in those likely to reap the benefits accruing from this new era of genomic medicine. As with other inequities in the health care system, non-European populations are being left out. A driving force in this inequity is that minority (or more specifically, non-European) populations are much less likely to participate in genomic research from which many translatable discoveries are made. In the U.S. ~ 40% of the population is of primarily non-European ancestry, and that proportion is only expected to increase. Globally, non-European ancestry populations make up 84% of the world’s population.11 Despite these numbers, only 22% of individuals included in genome-wide association studies (GWAS) are of non-European descent, according to an analysis of studies published through 2018.12 In recognition of this gap, a number of efforts have been made to increase genetic diversity and representation in GWAS studies across a range of non-EUR populations. These include the Human Heredity and Health in Africa (H3Africa) initiative, supported by NIH and the Wellcome Trust, and in the U.S., NIH-supported initiatives such as the All of Us Program and the Trans -Omics for Precision Medicine (TOPMed) Consortium.

The underrepresentation of minority populations in current genomic research leads to a significant European bias in terms of the composition of what variants are discovered. Because of differing population histories, many disease-causing and disease-associated variants present in Europeans may not be present in non-European populations or may be present at lower allele frequencies. Conversely, many disease-causing and disease-associated variants important in non-European populations may not be identifiable in European populations. As a result, it is well appreciated that polygenic risk scores (PRS), which are increasingly being used for risk stratification, significantly under-perform when applied to non-European populations because most have been generated based on GWAS results derived from European populations.11 Sound application of PRS requires well-powered GWAS within the ancestry group in which the PRS is to be applied.

Inclusion of ancestrally diverse populations in genomic studies is not only equitable, but also generates new genetic discoveries that may be translatable to members of all populations. Two examples are provided below, but there are many others. The first example is the discovery of a loss of function variant in APOC3 in a genetically isolated Amish community. This variant produces a dysfunctional APOC protein, which is unable to inhibit lipoprotein lipase and hepatic lipase from breaking down triglyceride. As a result, mutation carriers have decreased levels of serum triglycerides, and reduced risk of coronary heart disease.13, 14 Even though this mutation was discovered in the Amish, the idea of inhibiting APOC3 to decrease triglycerides and promote cardiovascular health is generalizable to individuals across ancestry groups. The second example is the 2016 discovery in an indigenous Samoan population of a mutation in CREBRF that is associated with a marked increase in body mass index, yet paradoxically, also which confers significant protection against type 2 diabetes.15, 16 Ongoing research of this gene may provide novel insights about fat storage and energy use that may help dissociate the co-occurrence of obesity and diabetes and reduce the burden of diabetes. As with the APOC3 example, the biological insights derived from this discovery can potentially benefit all people, including populations in whom the mutation is not present.

So why are minority and indigenous populations being left out of genomic research? The reasons for their underrepresentation are complex and multifactorial, but some of the barriers to participation may be confounded by mistrust by prior experiences with genetic research. Examples of historical transgressions experienced by some communities that have been well publicized include the conduct of unethical trials (e.g., Tuskegee Study of Untreated Syphilis17), the unauthorized use of tissues and DNA taken from patients without permission (e.g., the establishment of HeLa cell lines from Henrietta Lacks 18), and a lack of sensitivities to cultural norms of the population.19

Against this backdrop, Mudd-Martin et al. have prepared a thoughtful discussion outlining considerations for promoting the engagement of racial and ethnic minority groups and indigenous populations in genomic research. The authors provide an overview of ethical guidelines for genetic and genomic research, discuss special considerations regarding genetic and genomic research, and outline a series of practical considerations when conducting cardiovascular genetic and genomic research with minority and Indigenous populations. They discuss issues relating to establishing community collaborations, the informed consent process, transparency around sample use and in data analyses, dissemination of findings, return of genetic results, and protections surrounding data sharing.

Increasing the engagement of minority and underrepresented populations in genomic research is no easy task. Including the representation of more diverse populations in genome-wide association studies is a necessary, but not sufficient, first step. As described by Mudd-Martin et al., active engagement requires the establishment of trusting community partnerships. There is a lot of work to be done but bridging this gap in participation and access to genomic research must be a priority.

Citation


Mudd-Martin G, Cirino AL, Barcelona V, Fox K, Hudson M, Sun YV, Taylor JY, Cameron VA; on behalf of the American Heart Association Council on Genomic and Precision Medicine; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Considerations for cardiovascular genetic and genomic research with marginalized racial and ethnic groups and Indigenous peoples: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021;14:e000084. doi: 10.1161/HCG.0000000000000084

References


  1. Napolitano C, Mazzanti A and Priori SG. Genetic risk stratification in cardiac arrhythmias. Curr Opin Cardiol. 2018;33:298-303.
  2. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, Lai FY, Kaptoge S, Brozynska M, Wang T, Ye S, Webb TR, Rutter MK, Tzoulaki I, Patel RS, Loos RJF, Keavney B, Hemingway H, Thompson J, Watkins H, Deloukas P, Di Angelantonio E, Butterworth AS, Danesh J and Samani NJ. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention. J Am Coll Cardiol. 2018;72:1883-1893.
  3. Rao AS and Knowles JW. Polygenic risk scores in coronary artery disease. Curr Opin Cardiol. 2019;34:435-440.
  4. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT and Kathiresan S. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50:1219-1224.
  5. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA and Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94:317-23.
  6. Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, Moliterno DJ, Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R and Angiolillo DJ. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y(12) Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019;12:1521-1537.
  7. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH and Wadelius M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102:397-404.
  8. Leopold JA and Loscalzo J. Emerging role of precision medicine in cardiovascular disease. Circ Res. 2018;122:1302-1315.
  9. Cirino AL, Harris S, Lakdawala NK, Michels M, Olivotto I, Day SM, Abrams DJ, Charron P, Caleshu C, Semsarian C, Ingles J, Rakowski H, Judge DP and Ho CY. Role of genetic testing in inherited cardiovascular disease: A review. JAMA Cardiol. 2017;2:1153-1160.
  10. Streeten EA, See VY, Jeng LBJ, Maloney KA, Lynch M, Glazer AM, Yang T, Roden D, Pollin TI, Daue M, Ryan KA, Van Hout C, Gosalia N, Gonzaga-Jauregui C, Economides A, Perry JA, O'Connell J, Beitelshees A, Palmer K, Mitchell BD, Shuldiner AR and Regeneron Genetics C. KCNQ1 and Long QT Syndrome in 1/45 Amish: The Road From Identification to Implementation of Culturally Appropriate Precision Medicine. Circ Genom Precis Med. 2020;13:e003133.
  11. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM and Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51:584-591.
  12. Sirugo G, Williams SM and Tishkoff SA. The missing diversity in human genetic studies. Cell. 2019;177:26-31.
  13. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR and Shuldiner AR. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702-5.
  14. TG HDL Working Group of the Exome Sequencing Project National Heart Lung Blood Institute, Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, Lu Y, Tang ZZ, Zhang H, Hindy G, Masca N, Stirrups K, Kanoni S, Do R, Jun G, Hu Y, Kang HM, Xue C, Goel A, Farrall M, Duga S, Merlini PA, Asselta R, Girelli D, Olivieri O, Martinelli N, Yin W, Reilly D, Speliotes E, Fox CS, Hveem K, Holmen OL, Nikpay M, Farlow DN, Assimes TL, Franceschini N, Robinson J, North KE, Martin LW, DePristo M, Gupta N, Escher SA, Jansson JH, Van Zuydam N, Palmer CN, Wareham N, Koch W, Meitinger T, Peters A, Lieb W, Erbel R, Konig IR, Kruppa J, Degenhardt F, Gottesman O, Bottinger EP, O'Donnell CJ, Psaty BM, Ballantyne CM, Abecasis G, Ordovas JM, Melander O, Watkins H, Orho-Melander M, Ardissino D, Loos RJ, McPherson R, Willer CJ, Erdmann J, Hall AS, Samani NJ, Deloukas P, Schunkert H, Wilson JG, Kooperberg C, Rich SS, Tracy RP, Lin DY, Altshuler D, Gabriel S, Nickerson DA, Jarvik GP, Cupples LA, Reiner AP, Boerwinkle E and Kathiresan S. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22-31.
  15. Minster RL, Hawley NL, Su CT, Sun G, Kershaw EE, Cheng H, Buhule OD, Lin J, Reupena MS, Viali S, Tuitele J, Naseri T, Urban Z, Deka R, Weeks DE and McGarvey ST. A thrifty variant in CREBRF strongly influences body mass index in Samoans. Nat Genet. 2016;48:1049-54.
  16. Loos RJF. CREBRF variant increases obesity risk and protects against diabetes in Samoans. Nat Genet. 2016;48:976-978.
  17. Baker SM, Brawley OW and Marks LS. Effects of untreated syphilis in the negro male, 1932 to 1972: a closure comes to the Tuskegee study, 2004. Urology. 2005;65:1259-62.
  18. Jones BL, Vyhlidal CA, Bradley-Ewing A, Sherman A and Goggin K. If we would only ask: how Henrietta Lacks continues to teach us about perceptions of research and genetic research among African Americans today. J Racial Ethn Health Disparities. 2017;4:735-745.
  19. Guglielmi G. Facing up to injustice in genome science. Nature. 2019;568:290-293.

Science News Commentaries

View All Science News Commentaries

-- The opinions expressed in this commentary are not necessarily those of the editors or of the American Heart Association --